Detection of either of these markers in the primary tumor or metastatic lesions are predictive of endocrine or HER2 targeted therapy, respectively, whereas absence of these markers (combined with absence of Progesterone receptor (PgR)) defines the Triple-negative breast cancer (TNBC) subgroup where chemotherapy is the current standard treatment. Here, PGR is linked to neoplasm.